Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2017
Two cancer drug prices have already been hiked by 8% this year
3 July 2017 - Cancer drugs have already been criticised for too high price tags. ...
Posted by Michael Wonder on 03 Jul 2017
FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy
3 July 2017 - Today, the U.S. FDA cleared the expanded use of a cooling cap, DigniCap Cooling System, to ...
Posted by Michael Wonder on 03 Jul 2017
EMA and FDA encourage use of innovative approaches in the development of medicines for Gaucher disease
3 July 2017 - Approach aims to facilitate development of medicines for rare paediatric diseases in general. ...
Posted by Michael Wonder on 02 Jul 2017
Fears over a medical gold rush in cancer drug race
3 July 2017 - With almost 800 trials under way observers warn scientific rigour is being compromised. ...
Posted by Michael Wonder on 02 Jul 2017
High drug prices are bad. Cutting them could be worse.
30 June 2017 - It’s easy to be outraged by high drug prices. Yet under current circumstances, simply slashing them ...
Posted by Michael Wonder on 02 Jul 2017
Astellas submits supplemental new drug application for mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder
30 June 2017 - Astellas announced today the submission of a supplemental new drug application to the U.S. FDA seeking approval ...
Posted by Michael Wonder on 01 Jul 2017
Trump warms to old idea: kill health law now, and replace it later
30 June 2017 - With Senate Republicans already bogged down over how to dismantle the Affordable Care Act, President Trump ...
Posted by Michael Wonder on 01 Jul 2017
Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee
29 June 2017 - In the preamble of the United States Constitution, a primary goal of government was established: “to ...
Posted by Michael Wonder on 01 Jul 2017
FDA grants priority review to HIV monoclonal antibody and long-acting investigational anti-retroviral ibalizumab
30 June 2017 - Biologics license application accepted for review with a target action date of 3 January 2018. ...
Posted by Michael Wonder on 30 Jun 2017
Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to Rituxan (rituximab)
29 June 2017 - Celltrion and Teva Pharmaceutical Industries today announced that the U.S. FDA has accepted for review the biologics ...
Posted by Michael Wonder on 30 Jun 2017
FDA approves Vectibix (panitumumab) for use in wild type RAS metastatic colorectal cancer
29 June 2017 - Approved companion diagnostic tool strengthens precision medicine approach. ...
Posted by Michael Wonder on 29 Jun 2017
The crazy math behind drug prices
30 June 2017 - Intermediaries that negotiate to lower prices may cause them to increase, too. ...
Posted by Michael Wonder on 29 Jun 2017
In an overlooked corner of pharma, drastic price hikes hit medicines for radiology scans
29 June 2017 - Three years ago, pharmacist Dennis McClure was stunned by news from a key supplier. ...
Posted by Michael Wonder on 29 Jun 2017
Martin Shkreli’s trial shows just how angry people are about drug prices
29 June 2017 - Martin Shkreli isn't actually on trial for buying an obscure anti-parasitic drug used by AIDS patients ...
Posted by Michael Wonder on 29 Jun 2017
FDA is reviewing generic applications faster, but what about those carryover fees?
28 June 2017 - Now that the FDA plans to fast-track generic drug applications in hopes of spurring competition and ...